CCL2 and cancer: This provides a starting point to a more focused analyses regarding the role of these dominant immune mediators in patients with cancer, and offers an analytical tool that may be used to test additional biomarkers, relevant to MCP-1 (CCL2) and IP-10 (CXCL10) and in more detail describe the network of interactions in the absence or presence of therapeutic interventions, and resultant clinical outcomes, possibly identifying novel therapeutic targets and/or prognostic/predictive biomarkers.